Donald Trump was the first president in modern U.S. history to take office without holding a prior public office or serving in the military. This non-traditional path to the White House came with a distinctly corporate approach to economic and fiscal policy, one that both excited and unnerved investors in equal measure.
» Read more about: Will Markets Go Up Now That Trump Is President? »
Warren Buffett appeared to take a hard look at the market last year and decided he wanted to sell shares in plenty of companies, including Apple, Bank of America, and Charter Communications. His holding company, Berkshire Hathaway, even sold every share (nearly 4 million) in Floor & Decor Holdings. Overall, Buffett unloaded $133 billion in shares in 2024.
Ultragenyx may not have crossed your radar but it’s already in billionaire Stan Druckenmiller’s portfolio. What has he spotted in this novel therapies for rare and ultra-rare genetic diseases firm that convinced him to take a position?
Its focus on underserved patient populations, deep pipeline of innovative products, and strong track record in obtaining regulatory approvals make it an attractive long-term investment,
» Read more about: Billionaire Buys Stake In Gene Therapy Stock »
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over.
2024 was another banner year for the US stock market, with the S&P 500 notching a gain of 23%. Dwarfing even this return, though, was that of the Financial Select Sector SPDR ETF (XLF), which has delivered a 29.7% return over the last 12 months.
There is lots of speculation that the new President will be supportive of the financial sector so can XLF beat the market again in 2025,
Warren Buffett has spent 2024 stockpiling cash, even going so far as to sell off sizeable pieces of some of his largest investments. Recently, though, Berkshire Hathaway announced that it had made some modest acquisitions, including the addition of nearly 388,000 shares of domain name registry service Verisign (NASDAQ:VRSN).
These purchases brought Berkshire Hathaway’s holdings in Verisign to 13.2 million shares,
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
In the early days of e-commerce, few could have imagined just how quickly video-driven, real-time product demonstrations would reshape global retail. But here we are: In China alone, live streaming e-commerce revenue soared from a roughly $64 billion market in 2019 to more than $300 billion by 2021, according to data compiled by Deloitte.
This shift,
» Read more about: Forget AI, The Next Massive Trend Is Starting In 3,2,1… »
With the market near all-time highs, buying stocks can look like a worrisome proposition and it’s no surprise that many investors feel more comfortable sitting on the sidelines.
Staying out of the market entirely, though, presents an opportunity cost in the form of lost potential returns. So, just what can investors worried about the market’s performance and potential volatility do to limit their risks while still putting their money to work for them?
» Read more about: How To Trade When Markets Hit All-time Highs »
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »